ARCA biopharma Revenue and Competitors

Denver, CO USA

Location

$90.4M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • ARCA biopharma's estimated annual revenue is currently $3.5M per year.(i)
  • ARCA biopharma's estimated revenue per employee is $140,000
  • ARCA biopharma's total funding is $90.4M.

Employee Data

  • ARCA biopharma has 25 Employees.(i)
  • ARCA biopharma grew their employee count by -7% last year.

ARCA biopharma's People

NameTitleEmail/Phone
1
VP Finance & Chief Accounting OfficerReveal Email/Phone
2
VP, Regulatory Affairs and QualityReveal Email/Phone
3
Sr. Director, QualityReveal Email/Phone
4
Chief Operating OfficerReveal Email/Phone
5
CEO/PresidentReveal Email/Phone
6
SVP/General CounselReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.7M110%N/AN/A
#2
$2.8M1813%N/AN/A
#3
$70.2M453-1%N/AN/A
#4
$1.6M10-66%N/AN/A
#5
$3.7M24-8%N/AN/A
#6
$2.9M3728%N/AN/A
#7
$3.1M2025%N/AN/A
#8
$2.5M16-20%N/AN/A
#9
$9.1M590%N/AN/A
#10
$4.2M27-7%N/AN/A
Add Company

What Is ARCA biopharma?

ARCA biopharma, Inc. is a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases. ARCA biopharma began operations in 2005 and is headquartered in Broomfield, Colorado. The Company’s lead investigational product is Gencaro™ 1 (bucindolol hydrochloride), a genetically-targeted beta-blocker with unique pharmacology, in development for heart failure and other indications. ARCA’s New Drug Application for Gencaro for chronic heart failure, was accepted for filing by the U.S. Food and Drug Administration in September, 2008, and is currently under review by the FDA with a Prescription Drug User Fee Act (PDUFA) date of May 31, 2009.

keywords:N/A

$90.4M

Total Funding

25

Number of Employees

$3.5M

Revenue (est)

-7%

Employee Growth %

N/A

Valuation

N/A

Accelerator

ARCA biopharma News

2022-04-17 - Insider Buying: ARCA biopharma, Inc. (NASDAQ:ABIO) Insider ...

ARCA biopharma, Inc, a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular...

2022-04-17 - ARCA biopharma Establishes Special Committee of the Board of ...

ARCA biopharma is dedicated to developing genetically and other targeted therapies for cardiovascular diseases through a precision medicine...

2022-03-30 - ARCA biopharma Reports Topline Results for ASPEN-COVID-19 ...

ARCA biopharma is dedicated to developing genetically and other targeted therapies for cardiovascular diseases through a precision medicine...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$6.2M25-4%N/A
#2
N/A25-14%N/A
#3
$5.1M278%N/A
#4
$6.1M31-11%N/A
#5
$5.2M320%N/A